Patent classifications
C07D307/64
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:
##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:
##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
CANNABINOID DERIVATIVES
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
CANNABINOID DERIVATIVES
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
Furan surfactant compositions and methods
Chemical compositions, and related methods for synthesizing furan, such as oleo-furan, surfactants, include calcium, magnesium, ammonium and/or lithium cations and one of a number of furan derivatives. Methods for synthesizing such furan surfactants containing calcium, magnesium, ammonium and/or lithium cations can include chemical reagents and purification procedures to prepare furan surfactants containing calcium, magnesium, ammonium and/or lithium cations. These furan surfactant compositions can be free of dioxane and ethoxylate.
Furan surfactant compositions and methods
Chemical compositions, and related methods for synthesizing furan, such as oleo-furan, surfactants, include calcium, magnesium, ammonium and/or lithium cations and one of a number of furan derivatives. Methods for synthesizing such furan surfactants containing calcium, magnesium, ammonium and/or lithium cations can include chemical reagents and purification procedures to prepare furan surfactants containing calcium, magnesium, ammonium and/or lithium cations. These furan surfactant compositions can be free of dioxane and ethoxylate.
Aromatic surfactants
Disclosed are compounds of the Formula 1 wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a C.sub.2 or greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group. ##STR00001##
Aromatic surfactants
Disclosed are compounds of the Formula 1 wherein A is an aromatic moiety; H is a hydrophobic group comprising a main alkyl chain having from about 3 to about 26 carbon atoms and comprising a C.sub.2 or greater alkyl chain branched from the main alkyl chain; and K is a hydrophilic group. ##STR00001##